



Cells for Therapy and Research

26th Annual ROTH Conference
March 10th 2014

Forward Looking Statement

This presentation includes certain statements, estimates and projections with respect to the anticipated future business and performance of the Company, which are collectively referred to as forward-looking statements.

Forward-looking statements reflect various assumptions of management that may or may not prove to be correct, and are intended solely to convey our expectations or predictions about the future performance of the Company.

All forward-looking statements are inherently uncertain as they are based on our current expectations and assumptions concerning the future performance of our Company. This is not an offer to sell nor a solicitation to buy any security.

Who We Are

Stem Cell Regenerative Medicine Company


Successful Commercial Subsidiaries

- Biomedical products businesses addressing markets in excess of \$3 B
- \$5.66 M Revenues (TTM)
- Debt free
- Growing 20%+ per quarter (YOY)

Stem cell platform targeting therapeutics

- Solves real world problems
- Well protected, large IP estate
- Multiple therapeutic Indications
- Parkinson's program moving to clinical phase within 12 months

Core Strengths



Cutting-edge Science

- Proprietary
- Solves real-world problems
- Unique
- Powerful
- Ethically Superior
- Large Patent Estate




State of the art Manufacturing

- Research and GMP grade
- Human Cells and Media
- Efficient, Scalable
- Low-cost processes



Strong Revenue

- 20%+ quarterly revenues growth from subsidiaries
- Excellent Margins
- Synergistic infrastructure



Cell Therapy Programs

- Huge commercial opportunities
- Multiple indications
- Strong partnering prospects

Key Facts

Trading Symbol	OTCQB: ISCO
Corporate Headquarters	Carlsbad, CA
Stock Price(3/5/14)	\$0.24
52 Week Range	\$0.13 – \$0.34
Market Cap. (3/5/14)	\$36.23 M
Trading Volume (3/5/14)	811,832
Long-Term Debt	\$0
Cash on Hand (9/30/13)	\$1,792 K
Monthly burn (9/30/13)	\$470 K
Enterprise Value (3/5/14)	\$31.42 M
Revenue TTM	\$5.66 M
Full Time Employees	42
Audit firm	Mayer Hoffman McCann

Commercial Subsidiaries



Lifeline Cell Technology – a vertically integrated primary human cell research products business

- \$2.3 B Biomedical products market (bcc research 2009)
- Over 130 cells and optimized culture media products
- Branded and OEM products
 - Growing domestic sales force

Japan



Europe



Korea



China



Taiwan



India



Singapore, Malaysia, Indonesia



Commercial Subsidiaries (2)

Lifeline Skin Care - branded anti-aging stem cell skin care products

- \$800 M cosmeceutical market (Kline 2011)

Distribution Channels

DERMSTORE.
amazon.com

E-tailers

*Physicians
Spa/Med Spa*


International




Commercial Operations

Growing revenue diminishing net loss

Revenue / \$million



Loss from Dev. Activities



Excellent Gross Margins
2012 = 72%

2013 Results to be published next week

Platform Stem Cell Technology

Cutting-edge Science

Parthenogenesis. Human pluripotent stem cells from unfertilized eggs

Clinically superior for allogeneic therapy


Less rejection (histocompatible)

Pluripotent and Proliferative

Can be used to treat millions of patients and many diseases

Bypasses ethical concerns

No viable embryo created or destroyed



Intellectual Property Investment

Large patent portfolio including stem cell creation and differentiation methods

130 patents and licenses in 14 families

90 patents pending in 5 families

Significant peer-reviewed publications

Nature's Scientific Reports (2013)
Cell Stem Cell (2011,2012)



Manufacturing Capabilities




Human cell manufacturing capabilities suitable for early-stage clinical trials

- 13,125 sq.ft laboratory including 5 GMP manufacturing suites
- Largest private cryobank of histocompatible human pSC



R&D Targeting Multiple Diseases

Validating the stem cell platform for allogeneic therapy

Program	Target	Pre-Clinical	IND Track	Phase I
Human Neural Stem Cells	<i>Parkinson's disease</i>			
Hepatocyte-like cells	<i>Inherited metabolic liver diseases</i>			
Corneal cell/tissue	<i>Corneal blindness</i>			

Success unlocks significant additional value

Overview of Parkinson's Disease

2nd most common neurodegenerative disease

- 7-10 million people world-wide
- 60k new case / year (Parkinson's disease Foundation)
- \$2.5 billion in sales (2012)

Oral medications

- Dopamine replacement/ agonists
- Blockers of DA metabolism


Deep brain stimulation

Surgical implant of neuro-stimulator to modulate brain activity

- Limited to a sub-group of patients
- Unknown long-term safety


Fetal tissue implants:

- Ethically controversial
- Immune rejection by host
- Heterogeneity of the grafts
- Graft induced dyskinesia occur in subsets of patients



Disease continues to progress. No cure

Allogeneic Therapy for Parkinson's



Human Neural Stem Cells (hPNSC)

- Derived from platform technology

Self-renewing, multipotent

- Practical, unlimited supply of pure cells
- Not ethically controversial
- May be less immunogenic


Potential mechanism

- *Neuroprotection*: Produce factors that protect against cell death
- *Immunomodulation*: Migrate to areas of inflammation, inhibit immune response
- *Cell Replacement*: Differentiate into neuronal cell types lost in PD

Value driving - unlocks multiple additional indications

- Stroke, Amyotrophic Lateral Sclerosis, TBI

Manufacturing of hPNSC



Fully characterized

Scalable, low cost GMP protocol


- Suitable for pre-clinical and clinical studies
- Fully characterized *for purity, safety and functionality*

Published in peer-reviewed literature




Good Safety and Tolerability of hPNSC


Body weight of mice and rats within normal ranges



No visible tumors or pluripotent cells



Coronal section of the monkey brain stained with hematoxylin and eosin showing a normal morphology without the presence of ectopic tissue




Implantation site stained for human specific antibody STEM121 (in red) and OCT4 (in green), a marker of undifferentiated pluripotent stem cells. OCT4 is completely absent in the graft site.

Necropsies revealed all organs to be normal


Biodistribution analysis indicated no human cells found in any peripheral organs

Primate Proof-of-Concept hPNSC Data

Dopamine levels post mortem



Stable Parkscores and Healthy Behavior for duration of the study



Functional activity demonstrated in disease model (asymptomatic) primates



Complete GLP pre-clinical w/ clinical-grade hPNSC

- Primate pharmacology, toxicology, and efficacy Tumorigenicity study in SCID mice

Submit IND and begin FIM study w/ Duke

- Single arm, open label, dose escalating study
- < 20 subjects with idiopathic PD, UPDRS < 50
- PI - Prof. Mark Stacy, internationally renowned Neurologist with significant clinical trials experience in PD
- Stem cell therapy center of excellence

First company using PSC to treat PD

World-class Partners

Dr. Mark Stacy, MD

Vice Dean for Clinical Research, Neurology at Duke University School of Medicine

- **Clinical PI**
- **Neurologist**

Dr. Evan Y. Snyder, MD PhD

Chair of the FDA Advisory Committee for Cellular, Tissue and Gene Therapy UCSD and Director of Sanford-Burnham Stem Cell Research Center

- **Histology**
- **Data analysis**

Dr. D. Eugene Redmond Jr. MD

Professor of Psychiatry and of Neurosurgery, Yale School of Medicine

- **Primate Research**
- **Necropsies**

Dr. Jeanne Loring, PhD

Professor of Developmental Neurobiology, The Scripps Research Institute

- **Genomic analysis**
- **Characterization**

Growth Strategy

Expand Commercial Operations

- New commercial product lines
 - *Additional cell types, new anti-aging products*
- New business areas
 - *International distribution, Clinical-grade products, OEM products*

Near-term therapeutic milestones

- Parkinson's Disease pre-IND 1Q 2014 - **COMPLETE**
- GLP Pharm/Tox data 4Q 2014 - IND soon after
- Parkinson's FIM Phase I/II - 2015
- Additional therapeutic indications - 2015

Summary



Debt free commercial-stage Regenerative Medicine Company

Strong Commercial Operations

- Significant growth opportunities
- Products already on the market
- \$5.66 M in sales TTM

Proprietary Stem Cell Platform

- Solves real-world problems
- Initial target Parkinson's disease
- Numerous partnering opportunities
 - *Platform and therapy*
- Multiple additional indications unlocking huge additional value



*2013 RESULTS UNAUDITED



Questions?

ISCO.QB